Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
START Center for Cancer Care, San Antonio, Texas, USA.
Int J Cancer. 2021 Jul 15;149(2):403-408. doi: 10.1002/ijc.33556. Epub 2021 Mar 24.
Interleukin (IL)-10 has anti-inflammatory and CD8+ T-cell-stimulating properties. Pegilodecakin (pegylated recombinant human IL-10) induces intratumoral antigen-specific CD8 + T-cells and upregulates IFNγ and major histocompatibility complexes (MHC) I and II. Pegilodecakin has single-agent activity with manageable toxicity in advanced renal cell carcinama (aRCC) (data cutoff 24 March 2016). Pegilodecakin with pembrolizumab or nivolumab revealed clinical activity in aRCC (data cutoff 1 July 2018). Here, we report for the first time the results of pegilodecakin+ pazopanib, and final results for monotherapy and long-term follow-up with pegilodecakin + anti-programmed cell death 1 (anti-PD-1) inhibitors (data cutoff 19 February 2019). Phase 1/1b multi-cohort dose escalation IVY study enrolled 353 patients. Sixty-six patients with aRCC were treated with pegilodecakin alone or with pazopanib or anti-PD-1 inhibitor in cohorts A, G, H and I (data cutoff 19 February 2019). Primary endpoints included safety and tolerability. Secondary endpoint was tumor response by immune-related response criteria (irRC). Pegilodecakin plus nivolumab or pembrolizumab yielded median progression-free survival (mPFS) of 13.9 months and 6-month PFS probability of 60%, 76% 1-year overall survival (OS) probability and 61% 2-year OS probability. Pegilodecakin monotherapy produced mPFS of 1.8 months, 6-month PFS probability 25%, 1-year OS 50%, and 2-year OS 17%. Median OS was not reached in both combinations. Objective response rates (ORRs) were 33% with pazopanib and 43% with anti-PD-1. Most common Grade 3/4 treatment-related adverse events included anemia, thrombocytopenia and hypertriglyceridemia. In these heavily pretreated renal cell carcinama cohorts of IVY, pegilodecakin+anti-PD-1 inhibitor showed promising clinical activity. Safety profile of pegilodecakin alone and with anti-PD-1 inhibitors was consistent as previously reported.
白细胞介素 (IL)-10 具有抗炎和刺激 CD8+T 细胞的特性。 Pegilodecakin(聚乙二醇化重组人 IL-10)诱导肿瘤内抗原特异性 CD8+T 细胞,并上调 IFNγ 和主要组织相容性复合物 (MHC) I 和 II。 Pegilodecakin 在晚期肾细胞癌 (aRCC) 中具有单药活性和可管理的毒性(数据截止 2016 年 3 月 24 日)。Pegilodecakin 联合 pembrolizumab 或 nivolumab 在 aRCC 中显示出临床活性(数据截止 2018 年 7 月 1 日)。在这里,我们首次报告了 pegilodecakin+帕唑帕尼的结果,以及 pegilodecakin+抗程序性细胞死亡 1 (anti-PD-1) 抑制剂的单药治疗和长期随访的最终结果(数据截止 2019 年 2 月 19 日)。1/1b 期多队列剂量递增 IVY 研究纳入了 353 名患者。A、G、H 和 I 队列中有 66 名 aRCC 患者接受了 pegilodecakin 单药治疗或与帕唑帕尼或抗 PD-1 抑制剂联合治疗(数据截止 2019 年 2 月 19 日)。主要终点包括安全性和耐受性。次要终点是免疫相关反应标准 (irRC) 的肿瘤反应。Pegilodecakin 联合 nivolumab 或 pembrolizumab 的中位无进展生存期 (mPFS) 为 13.9 个月,6 个月 PFS 概率为 60%、76%的 1 年总生存期 (OS) 概率和 61%的 2 年 OS 概率。Pegilodecakin 单药治疗的 mPFS 为 1.8 个月,6 个月 PFS 概率为 25%,1 年 OS 为 50%,2 年 OS 为 17%。在这两种联合治疗中,中位 OS 均未达到。联合使用帕唑帕尼和抗 PD-1 的客观缓解率 (ORR) 分别为 33%和 43%。最常见的 3/4 级治疗相关不良事件包括贫血、血小板减少和高甘油三酯血症。在 IVY 的这些经过大量预处理的肾细胞癌队列中,Pegilodecakin+抗 PD-1 抑制剂显示出有希望的临床活性。Pegilodecakin 单药治疗和联合抗 PD-1 抑制剂的安全性与先前报道的一致。